Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer

TL;DR

Moderna's experimental melanoma vaccine uses mRNA technology and is personalized to each patient's tumor.
The vaccine, used alongside Merck's Keytruda immunotherapy, aims to prevent the recurrence or spread of advanced melanoma.
The treatment works by removing cancer's ability to hide from the immune system and then training the immune system to attack cancer cells.
A Phase 3 trial showed statistically significant and clinically meaningful improvement in keeping patients cancer-free longer.
Melanoma is the fifth most commonly diagnosed cancer in the U.S., with a significant number of annual deaths.

Continue reading the original article